Skip to main content

Drug Interactions between Cycrin and tovorafenib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

medroxyPROGESTERone tovorafenib

Applies to: Cycrin (medroxyprogesterone) and tovorafenib

Tovorafenib may reduce the blood levels of medroxyPROGESTERone, which may make it less reliable as a form of birth control. Alternative or additional methods of birth control should be used during treatment with tovorafenib and for at least 28 days after stopping treatment to avoid unintended pregnancy. This is particularly important because tovorafenib may cause fetal harm. Talk to your gynecologist or other healthcare professional for help in selecting an effective method of birth control that is best for you. Men with female partners of reproductive potential receiving tovorafenib should use a condom during the treatment period and for at least 2 weeks after stopping treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer